- Home
- RPTX vs LUNG Comparison
RPTX vs LUNG Comparison
Compare RPTX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- LUNG
- Stock Information
- Founded
- RPTX 2016
- LUNG 1995
- Country
- RPTX Canada
- LUNG United States
- Employees
- RPTX N/A
- LUNG N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- RPTX Health Care
- LUNG Health Care
- Exchange
- RPTX Nasdaq
- LUNG Nasdaq
- Market Cap
- RPTX 64.8M
- LUNG 65.6M
- IPO Year
- RPTX 2020
- LUNG 2020
- Fundamental
- Price
- RPTX $1.57
- LUNG $1.56
- Analyst Decision
- RPTX Strong Buy
- LUNG Buy
- Analyst Count
- RPTX 3
- LUNG 7
- Target Price
- RPTX $4.50
- LUNG $7.66
- AVG Volume (30 Days)
- RPTX 112.2K
- LUNG 1.0M
- Earning Date
- RPTX 08-08-2025
- LUNG 07-30-2025
- Dividend Yield
- RPTX N/A
- LUNG N/A
- EPS Growth
- RPTX N/A
- LUNG N/A
- EPS
- RPTX N/A
- LUNG N/A
- Revenue
- RPTX $250,000.00
- LUNG $90,549,000.00
- Revenue This Year
- RPTX N/A
- LUNG $17.92
- Revenue Next Year
- RPTX N/A
- LUNG $18.56
- P/E Ratio
- RPTX N/A
- LUNG N/A
- Revenue Growth
- RPTX N/A
- LUNG 18.24
- 52 Week Low
- RPTX $0.89
- LUNG $1.47
- 52 Week High
- RPTX $4.07
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- RPTX 57.39
- LUNG 30.27
- Support Level
- RPTX $1.54
- LUNG $1.47
- Resistance Level
- RPTX $1.60
- LUNG $1.63
- Average True Range (ATR)
- RPTX 0.05
- LUNG 0.15
- MACD
- RPTX 0.00
- LUNG -0.05
- Stochastic Oscillator
- RPTX 75.00
- LUNG 4.69
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.